Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Salt selection improved the developability of an inhaled poorly soluble compound

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: TEHLER, Ulrika (AstraZeneca, Pharmaceutical Sciences, Mölndal, Sweden)
  • Co-author(s): Ulrika Tehler: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
    Carolyn Stevenson: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
    Martin Lindsjö: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
    Ann-Kristin Ekelund: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
  • Abstract:

    Backgrounds

    Compound A is a poorly soluble compound intended for inhaled treatment of asthma. Initial toxicological evaluation in rodents suggested presence of undissolved material in the lung after repeat dosing.  Compound A as the free form is considered to be a poorly soluble compound with dissolution driven lung retention.

    Aims

    To minimize the

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses